ATE346041T1 - N-hydroxyformamid-derivate - Google Patents
N-hydroxyformamid-derivateInfo
- Publication number
- ATE346041T1 ATE346041T1 AT99902703T AT99902703T ATE346041T1 AT E346041 T1 ATE346041 T1 AT E346041T1 AT 99902703 T AT99902703 T AT 99902703T AT 99902703 T AT99902703 T AT 99902703T AT E346041 T1 ATE346041 T1 AT E346041T1
- Authority
- AT
- Austria
- Prior art keywords
- receptors
- hydroxyformamide derivatives
- tnf
- hydroxyformamide
- derivatives
- Prior art date
Links
- KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical class ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 abstract 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 abstract 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 abstract 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 abstract 1
- 108010092694 L-Selectin Proteins 0.000 abstract 1
- 102000016551 L-selectin Human genes 0.000 abstract 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9802073.8A GB9802073D0 (en) | 1998-01-30 | 1998-01-30 | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| GBGB9819574.6A GB9819574D0 (en) | 1998-09-08 | 1998-09-08 | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| US09/239,603 US6100266A (en) | 1998-01-30 | 1999-01-29 | Hydroxamic and carboxylic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE346041T1 true ATE346041T1 (de) | 2006-12-15 |
Family
ID=27269200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99902703T ATE346041T1 (de) | 1998-01-30 | 1999-01-29 | N-hydroxyformamid-derivate |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6100266A (de) |
| EP (1) | EP1051395B1 (de) |
| JP (1) | JP2002501943A (de) |
| CN (1) | CN100402496C (de) |
| AT (1) | ATE346041T1 (de) |
| AU (1) | AU735929B2 (de) |
| BR (1) | BR9908215A (de) |
| CA (1) | CA2317455C (de) |
| CY (1) | CY1106338T1 (de) |
| DE (1) | DE69934094T2 (de) |
| DK (1) | DK1051395T3 (de) |
| ES (1) | ES2277424T3 (de) |
| HU (1) | HUP0100597A3 (de) |
| IL (1) | IL137146A0 (de) |
| NO (1) | NO326266B1 (de) |
| PL (1) | PL200418B1 (de) |
| WO (1) | WO1999038843A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| JP2003501414A (ja) | 1999-06-04 | 2003-01-14 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼの阻害剤 |
| US20030199571A1 (en) * | 1999-12-24 | 2003-10-23 | Gordon Bruton | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
| EP1261590B1 (de) * | 2000-02-21 | 2012-04-11 | AstraZeneca AB | Piperidin- und piperazin-substituierte n-hydroxyformamiden zur verwendung als metalloproteinaseinhibitoren |
| JP2003524007A (ja) * | 2000-02-21 | 2003-08-12 | アストラゼネカ・アクチエボラーグ | アリールピペラジン類およびそれらのメタロプロテイナーゼ阻害剤（ｍｍｐ）としての使用 |
| EP1289980B1 (de) * | 2000-05-25 | 2004-11-17 | Smithkline Beecham Plc | Bicyclyl oder heterobicyclyl methanesulfonylamino-substituierte n-hydroxyformamide |
| FR2827859B1 (fr) * | 2001-07-30 | 2005-09-23 | Lipha | Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete |
| GB0119472D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| GB0119473D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca | Compounds |
| GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| US7511144B2 (en) | 2001-09-07 | 2009-03-31 | Kaken Pharmaceutical Co., Ltd. | Reverse hydroxamic acid derivatives |
| GB0128378D0 (en) * | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
| GB0128376D0 (en) | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel compounds |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| SE0301922D0 (sv) * | 2003-06-27 | 2003-06-27 | Astrazeneca Ab | Novel compounds |
| CA2630551C (en) * | 2005-11-24 | 2014-08-05 | Laboratoires Serono S.A. | N-hydroxyamide derivatives and use thereof |
| US20100226922A1 (en) * | 2006-06-08 | 2010-09-09 | Dorothea Maetzel | Specific protease inhibitors and their use in cancer therapy |
| PT2597084T (pt) * | 2010-07-08 | 2016-08-12 | Kaken Pharma Co Ltd | Derivado de n-hidroxiformamida e medicamento contendo o mesmo |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993021942A2 (en) * | 1992-05-01 | 1993-11-11 | British Biotech Pharmaceuticals Limited | Use of mmp inhibitors |
| CA2217857A1 (en) * | 1995-05-10 | 1996-11-14 | Darwin Discovery Limited | Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses |
| ES2183905T3 (es) * | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
| EP0994104A4 (de) * | 1996-06-27 | 2001-09-12 | Ono Pharmaceutical Co | Aryl-sulfid-, -sulfoxid- und -sulfon-derivate und arzneimittel die diese als aktiven inhaltsstoff enthalten |
| KR20000048639A (ko) * | 1996-09-27 | 2000-07-25 | 로렌스 티. 마이젠헬더 | 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산 |
| US5962481A (en) * | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| WO1998039316A1 (en) * | 1997-03-04 | 1998-09-11 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
| US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| NZ501166A (en) * | 1997-07-31 | 2001-12-21 | Abbott Lab | Reverse hydroxamate-containing compounds and their use as inhibitors of matrix metalloproteinases |
-
1999
- 1999-01-29 JP JP2000530080A patent/JP2002501943A/ja active Pending
- 1999-01-29 CN CNB998024937A patent/CN100402496C/zh not_active Expired - Fee Related
- 1999-01-29 CA CA2317455A patent/CA2317455C/en not_active Expired - Fee Related
- 1999-01-29 US US09/239,603 patent/US6100266A/en not_active Expired - Fee Related
- 1999-01-29 EP EP99902703A patent/EP1051395B1/de not_active Expired - Lifetime
- 1999-01-29 ES ES99902703T patent/ES2277424T3/es not_active Expired - Lifetime
- 1999-01-29 AT AT99902703T patent/ATE346041T1/de active
- 1999-01-29 PL PL342184A patent/PL200418B1/pl not_active IP Right Cessation
- 1999-01-29 IL IL13714699A patent/IL137146A0/xx active IP Right Grant
- 1999-01-29 DE DE69934094T patent/DE69934094T2/de not_active Expired - Lifetime
- 1999-01-29 BR BR9908215-2A patent/BR9908215A/pt not_active Application Discontinuation
- 1999-01-29 HU HU0100597A patent/HUP0100597A3/hu unknown
- 1999-01-29 WO PCT/GB1999/000313 patent/WO1999038843A1/en not_active Ceased
- 1999-01-29 AU AU22914/99A patent/AU735929B2/en not_active Ceased
- 1999-01-29 DK DK99902703T patent/DK1051395T3/da active
-
2000
- 2000-07-28 NO NO20003868A patent/NO326266B1/no not_active IP Right Cessation
-
2007
- 2007-02-22 CY CY20071100255T patent/CY1106338T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL137146A0 (en) | 2001-07-24 |
| NO326266B1 (no) | 2008-10-27 |
| NO20003868L (no) | 2000-07-28 |
| JP2002501943A (ja) | 2002-01-22 |
| PL200418B1 (pl) | 2009-01-30 |
| PL342184A1 (en) | 2001-05-21 |
| NO20003868D0 (no) | 2000-07-28 |
| HUP0100597A2 (hu) | 2001-08-28 |
| WO1999038843A1 (en) | 1999-08-05 |
| US6100266A (en) | 2000-08-08 |
| HK1029330A1 (en) | 2001-03-30 |
| BR9908215A (pt) | 2000-11-28 |
| DE69934094D1 (de) | 2007-01-04 |
| CA2317455C (en) | 2011-01-25 |
| CN100402496C (zh) | 2008-07-16 |
| DK1051395T3 (da) | 2007-04-02 |
| AU735929B2 (en) | 2001-07-19 |
| CN1289322A (zh) | 2001-03-28 |
| EP1051395B1 (de) | 2006-11-22 |
| HUP0100597A3 (en) | 2001-12-28 |
| CA2317455A1 (en) | 1999-08-05 |
| CY1106338T1 (el) | 2011-10-12 |
| AU2291499A (en) | 1999-08-16 |
| ES2277424T3 (es) | 2007-07-01 |
| EP1051395A1 (de) | 2000-11-15 |
| DE69934094T2 (de) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106338T1 (el) | Παραγωγα του ν-υδροξυφορμαμιδιου | |
| DK1119362T3 (da) | Anvendelse af tetracyclinderivater til forögelse af interleukin-10-produktion | |
| TR200200381T2 (tr) | Pirimidin-2,4,6-Trion Metalloproteinaz İnhibitorler. | |
| DK0728144T3 (da) | Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteinaser | |
| ES2193256T3 (es) | Aril pirroles 2-sustituidos, composiciones que contienen tales compuestos y procedimientos de uso. | |
| CY1109328T1 (el) | Ενωσεις θειενοδιβενζοαζουλενιου ως αναστολεις παραγοντα νεκρωσης ογκου | |
| ATE179431T1 (de) | Peptidische verbindungen und deren therapeutische verwendung als metalloproteinase-inhibitoren | |
| EA200100315A1 (ru) | Простые тетрагидропиридовые эфиры | |
| DK0988301T3 (da) | Imidazolylcykliske acetaler | |
| EA200001223A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| UA29466C2 (uk) | Фармацевтична композиція з антипухлинною активністю | |
| GB0209891D0 (en) | Novel compounds | |
| BR0308339A (pt) | Indazóis substituìdos com uma atividade anticancerosa | |
| ES2192839T3 (es) | Timosina beta 4 oxidada. | |
| DE69723863D1 (de) | Chinoline und deren therapeutische verwendung | |
| MY109722A (en) | Azaoxindole derivatives. | |
| EA200500849A1 (ru) | Новые соединения лапахона и способы их применения | |
| DE69620639D1 (de) | Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf) | |
| UY27772A1 (es) | Inhibidores triariloxiariloxipirimidin-2,4,6- triona de metaloproteinasa. | |
| DK1242410T3 (da) | Nye forbindelser | |
| AR024907A1 (es) | Uso de inhibidores de la produccion y/o accion de la il-18 y composiciones farmaceuticas formuladas con dichos inhibidores para el tratamiento demetastasis de tumores. | |
| BRPI0512751A (pt) | derivados de alfa-aminoácido com atividade antiinflamatória | |
| GT200100170A (es) | Compuestos con nucleos heterocicliclo-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion delasproteinas quinasas y los metodos para su uso. | |
| ATE394117T1 (de) | Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen | |
| IL137147A0 (en) | Hydroxamic and carboxylic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1051395 Country of ref document: EP |